Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
Verve Therapeutics has raised €56M across 1 funding round from 1 investor, most recently a Series A round in Jun 2020. Based in Cambridge, United States; founded 2018; active in Healthtech. Data as of 6 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-06-16 | Series A |
| €56M |
| GV |
| View deal → |
